Antifungal Activity of Statins and their Interaction with Amphotericin B Against Clinically Important Zygomycetes

被引：0
作者：
L. Galgóczy
Gyöngyi Lukács
Ildikó Nyilasi
T. Papp
Cs. Vágvölgyi
机构：
[1] University of Szeged,Department of Microbiology, Faculty of Science and Informatics
来源：
Acta Biologica Hungarica | 2010年 / 61卷
关键词：
Statin; amphotericin B; Zygomycetes; drug interaction; synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The in vitro antifungal activity of different statins and the combinations of the two most effective ones (fluvastatin and rosuvastatin) with amphotericin B were investigated in this study on 6 fungal isolates representing 4 clinically important genera, namely Absidia, Rhizomucor, Rhizopus and Syncephalastrum. The antifungal effects of statins revealed substantial differences. The synthetic statins proved to be more effective than the fungal metabolites. All investigated strains proved to be sensitive to fluvastatin. Fluvastatin and rosuvastatin acted synergistically and additively with amphotericin B in inhibiting the fungal growth in clinically available concentration ranges. Results suggest that statins combined with amphotericin B have a therapeutic potential against fungal infections caused by Zygomycetes species.
引用
收藏
页码：356 / 365
页数：9
相关论文
共 126 条
[1]  
Almyroudis N G(2007)In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents Antimicrob. Agents. Ch. 51 2587-2590
[2]  
Sutton D A(2007)Statins in the prevention of cardiovascular events in patients with renal failure Cardiovasc. Haematol. Disord. Drug. Targets 7 7-13
[3]  
Fothergill A W(2006)Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole Antimicrob. Agents. Ch. 50 96-103
[4]  
Rinaldi M G(2006)Zygomycosis: the re-emerging fungal infection Eur. J. Clin. Microbiol. Infect. Dis. 25 215-229
[5]  
Kusne S(2005)Mechanism of statin-mediated inhibition of small G-protein function J. Biol. Chem. 280 34202-34209
[6]  
Buemi M(1999)New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacolo. Therapeut. 84 413-428
[7]  
Floccari F(2005)Pharmacokinetic interactions between statins and fibrates Am. J. Cardiol. 96 44-49
[8]  
Nostra L(2007)Interactions between statins and FEMS Microbiol. Lett. 270 109-115
[9]  
Campo S(2009) antifungal protein (PAF) to inhibit the germination of sporan-giospores of different sensitive Mycoses. 52 447-453
[10]  
Caccamo C(2003)In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes Expt. Opin. Pharmacother. 4 141-164
12345678910